The GVHD product marketed in Japan has only been in the market place for 18 months as it is a very new treatment it will take time to gain market share and it is also achieving milestone payments for Mesoblast.GVHD is a devastating disease and is primarly used for stem cell transplants that have immune responses as well as organ and heamontonic blood transfusions that have not gone to plan. The patient size for this is rather limited when comparing to the other disease indications that Mesoblast are pursuing.There will be a far bigger market with FDA approval of the product!
Spelling!
Ann: Mesoblast Reports on Annual and Fourth Quarter Results, page-21
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |